Cargando…
High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
INTRODUCTION: HER2 gene amplification and protein overexpression (HER2+) define a clinically challenging subgroup of breast cancer with variable prognosis and response to therapy. Although gene expression profiling has identified an ERBB2 molecular subtype of breast cancer, it is clear that HER2+ tu...
Autores principales: | Staaf, Johan, Jönsson, Göran, Ringnér, Markus, Vallon-Christersson, Johan, Grabau, Dorthe, Arason, Adalgeir, Gunnarsson, Haukur, Agnarsson, Bjarni A, Malmström, Per-Olof, Johannsson, Oskar Th, Loman, Niklas, Barkardottir, Rosa B, Borg, Åke |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917012/ https://www.ncbi.nlm.nih.gov/pubmed/20459607 http://dx.doi.org/10.1186/bcr2568 |
Ejemplares similares
-
High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer
por: Reynisdottir, Inga, et al.
Publicado: (2013) -
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
por: Jönsson, Göran, et al.
Publicado: (2010) -
Evidence against PALB2 involvement in Icelandic breast cancer susceptibility
por: Gunnarsson, Haukur, et al.
Publicado: (2008) -
The risk allele of SNP rs3803662 and the mRNA level of its closest genes TOX3 and LOC643714 predict adverse outcome for breast cancer patients
por: Gudmundsdottir, Eydis Th, et al.
Publicado: (2012) -
The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability
por: Arason, Adalgeir, et al.
Publicado: (2019)